Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer

Menopause

Volumn 15, Issue SUPPL. 4, 2008, Pages 782-789

  Vogel, Victor G ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; TESTOSTERONE;

ADULT; AFRICAN AMERICAN; AGE; BODY MASS; BREAST BIOPSY; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; DIET; ENVIRONMENTAL FACTOR; ESTRADIOL BLOOD LEVEL; ETHNICITY; EXERCISE; FAMILY HISTORY; FEMALE; GENE MUTATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE; POSTMENOPAUSE; RACE; REVIEW; RISK MANAGEMENT; TESTOSTERONE BLOOD LEVEL; BREAST TUMOR; CARCINOMA IN SITU; GENETIC PREDISPOSITION; GENETICS; LUNG CARCINOMA; RISK ASSESSMENT; RISK FACTOR; TUMOR SUPPRESSOR GENE;

AGE FACTORS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMOGRAPHY; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS;

EID: 58149330837     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181788d88     Document Type: Review

References (62)

1. Vogel VG. High-risk populations as targets for breast cancer prevention trials. Prev Med 1991;20:86-100.
2. Vogel VG. Management of the high-risk patient. Surg Clin North Am2003;83:733-751.
3. Vogel VG. Epidemiology of breast cancer. In: Bland KI, Copeland EM, eds. The Breast: Comprehensive Management of Benign and Malignant Disease, 3rd ed, vol 1. Philadelphia: WB Saunders, 2004:341-354.
4. Gierach G, Vogel V. Epidemiology of breast cancer. In: Singletary SE, Robb GL, Hortobagyi GN, eds. Advanced Therapy of Breast Disease, 2nd ed. Hamilton, Ontario, Canada: BC Decker, 2004:58-83.
5. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomark Prev 2004;13:1558-1568.
6. Ferrer J, Neyro JL, Estevez A. Identification of risk factors for prevention and early diagnosis of asymptomatic post-menopausal women. Maturitas 2005;52(Suppl 1):S7-S22.
7. Gail MH, Anderson WF, Garcia-Closas M, et al. Absolute risk models for subtypes of breast cancer. J Natl Cancer Inst 2007;99:1657-1659.
8. Surveillance, Epidemiology, and End Results (SEER) Program. SEER* Stat Database: Incidence-SEER 13 Regs Limited-Use, November 2006 sub (1992-2004). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2007, based on the November 2006 submission. Available at: http://www.seer.cancer.gov. Accessed May 26, 2008.
9. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002;7:3-15.
10. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
11. Velie EM, Nechuta S, Osuch JR. Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. Breast Dis 2005-2006;24:17-35.
12. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer 2006;118:2373-2378.
13. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;143: 446-457.
14. Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007;14:169-187.
15. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353:275-285.
16. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297-301.
17. Morrow M, Vogel V, Ljung BM, et al. Evaluation and management of the woman with an abnormal ductal lavage. J Am Coll Surg 2002; 194:648-656.
18. Vogel VG. Atypia in the assessment of breast cancer risk: implications for management. Diagn Cytopathol 2004;30:151-157.
19. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-237.
20. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92:1217-1227.
21. Lakhani SR, Audretsch W, Cleton-Jensen AM, et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer 2006;42:2205-2211.
22. Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist 2004;9:13-24.
23. Rubinstein WS. Hereditary breast cancer in Jews. Fam Cancer 2004; 3:249-257.
24. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006;25:5898-5905.
25. Hwang ES, McLennan JL, Moore DH, et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25:642-647.
26. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005;293:964-969.
27. Boyd NF, Martin LJ, Yaffe MJ, et al. Mammographic density: a hormonally responsive risk factor for breast cancer. J Br Menopause Soc2006;12:186- 193.
28. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-236.
29. Tice JA, Cummings SR, Ziv E, et al. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115-122.
30. Tamimi RM, Byrne C, Colditz GA, et al. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-1187.
31. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-395.
32. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215-1226.
33. Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001;19:3111-3116.
34. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287:216-220.
35. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 2005-2006;24:3-15.
36. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a womans predicted breast cancer risk? J Clin Oncol 2006; 24:1823-1830.
37. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
38. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst2006;98:110-115.
39. Vogel VG, Taioli E. Have we found the ultimate risk factor for breast cancer? J Clin Oncol 2006;24:1791-1794.
40. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276: 1404-1408.
41. Linos E, Holmes MD, Willett WC. Diet and breast cancer. Curr Oncol Rep 2007;9:31-41.
42. Friedenreich CM. Physical activity and breast cancer risk: the effect of menopausal status. Exerc Sport Sci Rev 2004;32:180-184.
43. Key TJ, Allen NE, Spencer EA, et al. Nutrition and breast cancer. Breast2003;12:412-416.
44. Kim Y-I. Does a high folate intake increase the risk of breast cancer? Nutr Rev 2006;64:468-475.
45. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295: 629-642.
46. Moorman , Patricia G, Terry , Paul D. Consumption of dairy products and the risk of breast cancer: a review of the literature. Am J Clin Nutr2004;80:5-14.
47. Starek A. Estrogens and organochlorine xenoestrogens and breast cancer risk. Int J Occup Med Environ Health 2003;16:113-124.
48. Negri E, Bosetti C, Fattore E, La Vecchia C. Environmental exposure to polychlorinated biphenyls (PCBs) and breast cancer: a systematic review of the epidemiological evidence. Eur J Cancer Prev 2003;12: 509-516.
49. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
50. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-1548.
51. Bondy ML, Lustbader ED, Halabi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1984;86:620-625.
52. Spiegelman D, Colditz GA, Hunter D, et al. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst1994;86:600-607.
53. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-366.
54. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130.
55. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007;99:1782-1792.
56. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006;295:2727-2741.
57. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;7:439-448.
58. Bondy ML, Newman LA. Assessing breast cancer risk: evolution of the Gail model. J Natl Cancer Inst 2006;98:1172-1173.
59. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98:1204-1214.
60. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007;99:1695-1705.
61. Rastogi P. Chemoprevention in postmenopausal women. Menopause2008;15:810-815.
62. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-532.